Golub Capital BDC, Inc. Schedules Release of Fiscal Year 2025 Third Quarter Results
Golub Capital BDC, Inc. will host an earnings conference call at 10:30 a.m. (Eastern Time) on Tuesday, August 5, 2025 to discuss its quarterly financial results.
All interested parties may participate in the conference call by dialing (888) 330-3529 approximately 10-15 minutes prior to the call; international callers should dial (646) 960-0656. Participants should reference Golub Capital BDC, Inc. when prompted, or reference conference ID number 5111111. An archived replay of the call will be available shortly after the call until 11:59 p.m. (Eastern Time) on August 12, 2025. To hear the replay, please dial (800) 770-2030. International dialers, please dial (647) 362-9199. For all replays, please reference program ID number 5111111.
ABOUT GOLUB CAPITAL BDC, INC.
Golub Capital BDC, Inc. ('GBDC') is an externally-managed, non-diversified closed-end management investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. GBDC invests primarily in one stop and other senior secured loans to middle market companies that are often sponsored by private equity investors. GBDC's investment activities are managed by its investment adviser, GC Advisors LLC, an affiliate of the Golub Capital LLC group of companies ('Golub Capital').
ABOUT GOLUB CAPITAL
Golub Capital is a market-leading, award-winning direct lender and experienced private credit manager. The firm specializes in delivering reliable, creative and compelling financing solutions to companies backed by private equity sponsors. Golub Capital's sponsor finance expertise also forms the foundation of its Broadly Syndicated Loan and Credit Opportunities investment programs. Golub Capital nurtures long-term, win-win partnerships that inspire repeat business from private equity sponsors and investors.
As of April 1, 2025, Golub Capital had over 1,000 employees and over $75 billion of capital under management, a gross measure of invested capital including leverage. The firm has offices in North America, Europe, Asia and the Middle East. For more information, please visit golubcapital.com.
FORWARD-LOOKING STATEMENTS
This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those expressed or implied in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission. Golub Capital BDC, Inc. undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Could Apple Soon Lose Its Top Position in Warren Buffett's Portfolio?
Apple has been one of Warren Buffett's largest holdings for years, but the distance between second spot has been shrinking. Buffett has been unloading Apple stock and it has also been falling in value. 10 stocks we like better than Apple › Warren Buffett has famously referred to iPhone maker Apple (NASDAQ: AAPL) as "probably the best business I know in the world." It's long been one of Buffett's favorite stocks, and it has been a staple in the Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) portfolio for years. But while it still remains the top holding in the portfolio, it may not stay in that position for much longer. Here's why that could happen and what it might mean for investors. It wasn't all that long ago when Apple was easily the largest holding in Berkshire's portfolio, and it wasn't even close. As of the end of 2023, Apple accounted for half of the entire portfolio and was worth more than $174 billion. The next-largest holding was Bank of America, which accounted for just 10% of the portfolio and was worth a little less than $35 billion at the time. The idea of Apple falling in the second spot just didn't look like a conceivable scenario. However, with Buffett selling Apple stock since then and shares of the tech giant also falling, that has resulted in a much different makeup of Berkshire's portfolio today. Berkshire's position in Apple has been trimmed by two-thirds and was worth nearly $67 billion as of the end of March. While that was still good enough for the top spot and represented 26% of all holdings, the second spot, which belonged to American Express, accounted for 16% of the portfolio and was worth nearly $41 billion. Today, the gap is even thinner, with Apple's share of the Berkshire portfolio coming in at just under 22% versus nearly 17% for American Express. Apple has been a beloved Buffett stock for years, but amid fears of a rising capital gains tax rate, the billionaire investor has been drastically reducing his company's position in the tech giant. Even if Buffett doesn't sell any more Apple shares, the stock's falling valuation could lead to it falling to the second-largest holding in the fund in the near future. Shares of Apple are down 6% over the past 12 months, while American Express has risen by more than 37% over that stretch (returns as of July 7). Investors have been bearish on Apple over the slow rollout of artificial intelligence (AI) features for its latest iPhone. Without a drastic change and a way to convince investors that it's still a good growth stock and the business isn't falling behind its rivals, this downward trend may continue. In the longer term, I could see Apple even leaving the Berkshire portfolio permanently. Buffett is stepping down as CEO this year, at which point Greg Abel will take over. Under new leadership, there could be greater changes ahead, including potentially exiting the company's position in Apple and opting for stocks that may be better positioned for growth in AI. While that's not a guarantee, it may be a plausible scenario, especially if Apple struggles to show that it can keep up with its key competitors. Whether Apple is or isn't in Berkshire's portfolio shouldn't dictate whether you buy the stock or not. It may impact the stock in the short term as Buffett fans may follow suit and sell shares of Apple as well. Ultimately, however, whether you buy the stock or not should depend on your long-term investing strategy. If you're willing to be patient and invest in a blue chip stock that has phenomenal financials, including annual free cash flow of around $100 billion, then this can be a good investment to put into your portfolio today. While it may be a volatile road ahead for Apple, with a strong ecosystem of products and ample resources at its disposal, I'm confident the company can be a big player in AI and turn things around -- it's just a matter of how long it may take for that to happen. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $695,481!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $969,935!* Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Bank of America is an advertising partner of Motley Fool Money. American Express is an advertising partner of Motley Fool Money. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Bank of America, and Berkshire Hathaway. The Motley Fool has a disclosure policy. Could Apple Soon Lose Its Top Position in Warren Buffett's Portfolio? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions. Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib as well as for working capital and general corporate purposes. J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering. The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission (SEC) on February 10, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on July 8, 2025. A final prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained at the SEC's website at or by request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@ and postsalemanualrequests@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the completion of the public offering and the use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the underwritten public offering; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the underwritten public offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on February 10, 2023 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplement related to this offering. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi WaarichSenior Director, Investor
Yahoo
2 hours ago
- Yahoo
Toast (TOST) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest close session, Toast (TOST) was down 2.88% at $43.54. The stock's change was less than the S&P 500's daily loss of 0.07%. At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq gained 0.03%. Coming into today, shares of the restaurant software provider had gained 3.18% in the past month. In that same time, the Computer and Technology sector gained 5.58%, while the S&P 500 gained 3.94%. Investors will be eagerly watching for the performance of Toast in its upcoming earnings disclosure. On that day, Toast is projected to report earnings of $0.23 per share, which would represent year-over-year growth of 1050%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.53 billion, up 23.45% from the year-ago period. For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.95 per share and a revenue of $6 billion, signifying shifts of +3066.67% and +21.06%, respectively, from the last year. Any recent changes to analyst estimates for Toast should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Toast presently features a Zacks Rank of #4 (Sell). In the context of valuation, Toast is at present trading with a Forward P/E ratio of 47.29. This indicates a premium in contrast to its industry's Forward P/E of 29.09. The Internet - Software industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 61, putting it in the top 25% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Toast, Inc. (TOST) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
